ProfileGDS5678 / 1460646_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 79% 77% 79% 79% 81% 82% 80% 77% 78% 79% 78% 79% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.5197679
GSM967853U87-EV human glioblastoma xenograft - Control 25.4968179
GSM967854U87-EV human glioblastoma xenograft - Control 35.2405477
GSM967855U87-EV human glioblastoma xenograft - Control 45.7017679
GSM967856U87-EV human glioblastoma xenograft - Control 55.5622379
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.541981
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.7842482
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.690380
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.2665877
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.3731478
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.5115279
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.3874678
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.4785679
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.4180678